Abarelix
Also known as: Abarelix, Abarelix acetate, GnRH antagonist decapeptide, Plenaxis, PPI-149, R-3827
Source Abarelix at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Abarelix is a synthetic decapeptide that acts as a gonadotropin‑releasing hormone (GnRH) antagonist. It was investigated for rapid hormonal castration in advanced prostate cancer and, in women, for conditions such as endometriosis and hormone‑dependent breast cancer. Although it received FDA approval in 2004, development was later discontinued and the drug is now listed as withdrawn.
Mechanism of Action
Abarelix binds competitively to the GnRH (LHRH) receptor in the pituitary gland, preventing the normal GnRH‑stimulated release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). The resulting fall in LH suppresses testicular testosterone production in men and ovarian estrogen production in women. By blocking the receptor directly, it avoids the initial surge of LH and testosterone that occurs with GnRH agonists, leading to a faster onset of castration‑level hormone suppression.
What the Research Shows
Phase II and III clinical trials in advanced symptomatic prostate cancer showed that abarelix rapidly reduced testosterone and FSH without the flare phenomenon typical of GnRH agonists. Patients experienced improvements in pain, urinary symptoms and avoided bilateral orchiectomy after 12 weeks of treatment. Comparative studies reported a safety profile similar to agonist monotherapy but a higher incidence of immediate‑onset systemic allergic reactions. Development continued with depot formulations for prostate cancer and endometriosis, but FDA review highlighted allergic events and inconsistent testosterone suppression beyond three months, leading to rejection of the original NDA and eventual withdrawal of the product.
Reported Benefits
Clinical data indicate that abarelix can achieve rapid castration‑level testosterone suppression, eliminating the transient testosterone surge seen with agonists. This rapid onset may reduce disease flare in metastatic prostate cancer. Studies reported better pain control, improved urinary function, and lower need for surgical castration after sustained treatment. The antagonist also lowers FSH more profoundly than agonist therapy, which may be advantageous in certain hormone‑dependent conditions.
Limitations of the Evidence
Abarelix development was halted after FDA concerns about allergic reactions and variable maintenance of testosterone suppression beyond three months. The drug never achieved broad regulatory approval outside the brief 2004 FDA clearance and is now withdrawn, limiting its availability. Long‑term efficacy and safety data are sparse, and the higher rate of immediate systemic allergic events compared with standard GnRH agonists remains a notable drawback.
Safety Considerations
The most frequently reported adverse effect in clinical trials was immediate‑onset systemic allergic reactions, occurring more often than with comparator GnRH agonists. Overall safety was comparable to agonist monotherapy, but clinicians were advised to monitor patients closely for hypersensitivity during and after injection. No specific cardiovascular safety signals were highlighted in the abstracts, but the lack of a testosterone surge may reduce flare‑related complications.
How It Is Administered
Abarelix is administered by intramuscular injection. Both depot (long‑acting) and non‑depot formulations have been investigated, with depot versions intended for less frequent dosing in prostate cancer and endometriosis. The drug is supplied as an injectable suspension for subcutaneous or intramuscular use.
Routes of Administration
Goals & Uses
- Palliative treatment of advanced prostate cancerOncologyHigh
- Reduction of PSA levelsBiomarker ResponseHigh
- Testosterone suppression to castrate levelsHormonal TherapyHigh
- Prevention of testosterone flareOncology / Hormonal SafetyHigh
- Advanced prostate cancerOncologyHigh
Contraindications
- Hypersensitivity to abarelix or excipientsAllergyHigh
- Patients who can be managed with LHRH agonistsClinical SuitabilityModerate
- Female sex (women of childbearing potential)PopulationHigh
- History of serious hypersensitivity to abarelixAllergyHigh
- Hypersensitivity to abarelix or any excipientsAllergyHigh
- Pediatric usePopulationHigh
- QT prolongation / long QT syndromeCardiacHigh
Adverse Effects
- Injection site reactionsLocalCommon
- QTc prolongationCardiacUncommon
- Elevated transaminasesHepaticUncommon
- Hot flashesEndocrine / VasomotorCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Anaphylactic reactionsSystemicRare
- Immediate-onset systemic allergic reactionImmunologicUncommon
- Hot flushesVasomotorCommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Decreased libido / erectile dysfunctionSexual / EndocrineCommon
Drug Interactions
- CYP450 substratesLow
- QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)High
- Anticoagulants (warfarin)Moderate
Population Constraints
- Pediatric patientsAgeAbsolute
- Patients with pre-existing QT prolongationCardiacRelative
- Patients with hepatic impairmentOrgan FunctionRelative
- WomenSexAbsolute
- Male patients onlySexAbsolute
Regulatory Status
- European UnionWithdrawnApproved: advanced prostate cancerWithdrawn from market in 2009 due to safety concerns
- United StatesUnapprovedNever received FDA approval
- United KingdomWithdrawnApproved: advanced prostate cancerFollowed EU withdrawal
Approved in EU (2003) as Plenaxis, later withdrawn; never approved in the US.
Evidence & Sources
- Journal ArticleModerateDoehn C, Jocham D2000-01-01T00:00:00.000000Z
- Journal ArticleModeratePatel S, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerate2003-01-01T00:00:00.000000Z
- Journal ArticleModerateDebruyne F, Bhat G, Garnick MB2006-01-01T00:00:00.000000Z
- Journal ArticleModerateDellis A, Papatsoris A2017-01-01T00:00:00.000000Z
- Journal ArticleModerateKirby RS, Fitzpatrick JM, Clarke N2009-01-01T00:00:00.000000Z
Frequently Asked Questions
How does abarelix differ from traditional GnRH agonists?
Abarelix blocks the GnRH receptor directly, preventing LH and testosterone surges that occur with agonists. This results in faster hormonal castration without the need for anti‑androgen co‑therapy.
Why is abarelix no longer available?
Development was discontinued after the FDA raised concerns about allergic reactions and inconsistent testosterone suppression. The product was subsequently withdrawn and never marketed widely.
What adverse reactions should be watched for during treatment?
Clinical trials reported a higher incidence of immediate systemic allergic reactions. Patients should be observed for signs of hypersensitivity during and after injection, and appropriate emergency measures should be ready.
Can abarelix be used for conditions other than prostate cancer?
Early studies explored its use in endometriosis, breast cancer, and other hormone‑dependent disorders, but development in these areas was halted and no approved indications exist.
What is the route and formulation of abarelix?
The drug is delivered as an intramuscular injectable suspension, with both depot (long‑acting) and non‑depot formulations studied in clinical trials.
What is Abarelix used for?
Abarelix is educationally associated with: Palliative treatment of advanced prostate cancer, Reduction of PSA levels, Testosterone suppression to castrate levels, Prevention of testosterone flare, Advanced prostate cancer. Educational only — not medical advice.
How is Abarelix administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Abarelix?
Reported adverse effects include: Injection site reactions, QTc prolongation, Elevated transaminases, Hot flashes, Nausea, Anaphylactic reactions, Immediate-onset systemic allergic reaction, Hot flushes, Elevated liver enzymes, Decreased libido / erectile dysfunction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Abarelix?
Recorded contraindications: Hypersensitivity to abarelix or excipients, Patients who can be managed with LHRH agonists, Female sex (women of childbearing potential), History of serious hypersensitivity to abarelix, Hypersensitivity to abarelix or any excipients, Pediatric use, QT prolongation / long QT syndrome. Consult a qualified clinician before use.